CORT

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 28, 2023
CORT, Diabetes, Neck, MD, Depression, Anxiety, Disease, Syndrome, Irritability, Investment, Patient, NDA, Corcept Therapeutics, Growth, Cushing's syndrome, Doctor of Pharmacy, NASH, Atrophy, Fatigue, Neuroinflammation, GRACE, Woman, Prevalence, Ageing, ALS, Pharmaceutical industry, Video game, Cryptocurrency

Net income was $16.6 million in the fourth quarter of 2022, compared to $32.1 million in the fourth quarter of 2021.

Key Points: 
  • Net income was $16.6 million in the fourth quarter of 2022, compared to $32.1 million in the fourth quarter of 2021.
  • Cash and investments of $436.6 million at December 31, 2022 compared to $335.8 million at December 31, 2021.
  • We are providing 2023 revenue guidance of $430 - $450 million,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
  • Corcept holds patents directed to the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism.

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on: 
Tuesday, February 14, 2023
CORT, Pharmaceutical industry, Internet service provider, Video game

MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023.

Key Points: 
  • MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023.
  • The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
  • To access the conference call, please dial 877-407-8029 from the United States or +1-201-689-8029 internationally.

Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation

Retrieved on: 
Monday, February 13, 2023
Therapy, CORT, District court, Corcept Therapeutics, Pharmaceutical industry

MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has reached a preliminary settlement of all claims in the purported securities class action against Corcept and certain of its executive officers captioned Melucci v. Corcept Therapeutics Incorporated, et al., Case No.

Key Points: 
  • MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has reached a preliminary settlement of all claims in the purported securities class action against Corcept and certain of its executive officers captioned Melucci v. Corcept Therapeutics Incorporated, et al., Case No.
  • 5:19-cv-01372-LHK, which was pending in the United States District Court for the Northern District of California.
  • Under the proposed settlement, Corcept has agreed to make a one-time payment of $14.0 million, which will be covered in full by Corcept’s insurers.

4SITE by CORT, Cresa partner to help occupiers make data-driven decisions about their real estate

Retrieved on: 
Monday, February 6, 2023
Commercial Building & Real Estate, Technology, Mobile, Wireless, Construction & Property, Human Resources, Professional Services, Software, Hardware, Data Analytics, Privacy, Workplace, Intelligence, CORT, Partnership, Cresa

Cresa, the world’s largest occupier-centric commercial real estate firm, and 4SITE by CORT, a sensor-based workplace occupancy and space utilization platform provider, have today announced their partnership to help office occupiers optimize their workplaces.

Key Points: 
  • Cresa, the world’s largest occupier-centric commercial real estate firm, and 4SITE by CORT, a sensor-based workplace occupancy and space utilization platform provider, have today announced their partnership to help office occupiers optimize their workplaces.
  • In a trend prompted by the pandemic and furthered by projected economic headwinds, many occupiers are seeking ways to reduce underutilized space and real estate spend.
  • The partnership between Cresa and 4SITE is rooted in a shared commitment to helping occupiers make data-driven decisions about their workplaces.
  • "The 4SITE platform further enhances the Cresa workplace strategy advisory capability and will help fuel greater understanding of ongoing workplace trends, enabling both parties to make more insightful recommendations in the future."

Corcept Therapeutics Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Thursday, December 29, 2022
CORT, Record, Therapy, Corcept Therapeutics, Sale

LOS ANGELES, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Key Points: 
  • LOS ANGELES, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT

Retrieved on: 
Wednesday, December 28, 2022
Class Action Lawsuit, Professional Services, Legal, Titan, CORT, Corcept Therapeutics, Advertising, I-Space (Chinese company), Security (finance)

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).

Key Points: 
  • WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).
  • The Rosen Law firm is preparing a class action seeking recovery of investor losses.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.

Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals

Retrieved on: 
Thursday, December 8, 2022
Prostate, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Microdeletion syndrome, Ovary, Hyperglycemia, Judgement, Liver disease, United States district court, Federal Trade Commission, Food, ALS, FDA, Abbreviated New Drug Application, NASH, Wilms' tumor, Court, United States federal executive departments, DOJ, Prediabetes, Amyotrophic lateral sclerosis, MD, Fatty liver disease, CORT, ANDA, Patent, Weight gain, Patient, Corcept Therapeutics, FTC, Pharmaceutical industry

In connection with the settlement, Corcept has granted Hikma the right to sell a generic version of Korlym in the United States beginning October 1, 2034 or earlier under circumstances customary for settlement agreements of this type.

Key Points: 
  • In connection with the settlement, Corcept has granted Hikma the right to sell a generic version of Korlym in the United States beginning October 1, 2034 or earlier under circumstances customary for settlement agreements of this type.
  • “It is gratifying to put an end to this litigation,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
  • As required by law, Corcept and Hikma will submit the agreement to the United States Federal Trade Commission (FTC) and the United States Department of Justice (DOJ) for review.
  • Similar patent litigation brought by Corcept against Teva Pharmaceuticals USA, Inc. remains pending.

Corcept Therapeutics Provides Miricorilant Clinical Development Update

Retrieved on: 
Thursday, December 8, 2022
Prostate, Ovary, Liver, Intellectual property, Hunting, Liver disease, Food, Journal of Clinical Psychopharmacology, ALS, Probability, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASH, Wilms' tumor, Doctor of Pharmacy, Fatty liver disease, CORT, Weight gain, COVID-19, Patient, Corcept Therapeutics, Pharmaceutical industry

“Miricorilant did not reverse AIWG in either our GRATITUDE or GRATITUDE II trials,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.

Key Points: 
  • “Miricorilant did not reverse AIWG in either our GRATITUDE or GRATITUDE II trials,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • “Miricorilant continues to demonstrate great promise as a treatment for NASH,” added Dr. Guyer.
  • In this press release, forward-looking statements include those concerning the development of miricorilant, including its clinical attributes, regulatory approvals, mandates and oversight, and other requirements; our trials involving miricorilant, including their design, results and probability of success.
  • We disclaim any intention or duty to update forward-looking statements made in this press release.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Friday, December 16, 2022
Class Action Lawsuit, Professional Services, Legal, Light, Certification, CORT, Ethics, Suite, Corcept Therapeutics, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Thursday, December 15, 2022
Class Action Lawsuit, Professional Services, Legal, Light, Certification, CORT, Ethics, Suite, Corcept Therapeutics, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.